FDA To Lower Scrutiny Of CMV Tests Used In Transplant Patients
Executive Summary
A proposed rule from the US agency would move the in vitro diagnostics from high-risk class III to class II with special controls, eliminating the requirement for a PMA.
You may also be interested in...
US FDA Panel To Meet on Transplant IVDs, Test For Managing Antibiotics
The agency's microbiology devices advisory panel will hold a two-day meeting next month focused on classification of transplant IVDs and potential 510(k) requirements for a test that can help detect and monitor sepsis and other bacterial infection.
Merit Medical To Pay $18M To Settle Kickback Case
The US Department of Justice says the company provided advertising assistance and educational grants to health care providers that used its embolization devices.
Priority Lane: Guidances On Risky Devices, 510(k) Reform Top FDA’s To-Do List
The US FDA hopes to finalize or issue draft guidance documents on about 30 topics in fiscal year 2021.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
This content is free with registration!
Start a free trial today!
Register to keep reading and receive our free email digests